Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

480
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
480
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

638
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
638
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

659
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
659
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

182
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
182
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

518
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
518
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

612
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
612

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Haematologica·2026
Same author

Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed mice.

Scientific reports·2026
Same author

Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review.

European journal of human genetics : EJHG·2026
Same author

Effect of pasteurized <i>Akkermansia muciniphila</i> MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut <i>Akkermansia</i> levels.

Gut microbes·2026
Same author

Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseases.

Atherosclerosis·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Nov 24, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.8K

Inflammation-induced cholestasis in cancer cachexia.

Morgane M Thibaut1, Martina Sboarina1, Martin Roumain2

  • 1Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.

Journal of Cachexia, Sarcopenia and Muscle
|December 22, 2020
PubMed
Summary

Cancer cachexia involves liver alterations, with impaired bile acid metabolism and increased hepatic inflammation. Targeting bile acids or interleukin-6 shows therapeutic potential in cachexia models.

Keywords:
Bile acidsCholestyramineHepatobiliary transport systemIL-6Liver

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

53.7K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.1K

Related Experiment Videos

Last Updated: Nov 24, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.8K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

53.7K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.1K

Area of Science:

  • Hepatology
  • Metabolic Syndrome
  • Cancer Biology

Background:

  • Cancer cachexia is a metabolic syndrome causing significant mortality.
  • Hepatic alterations, beyond muscle wasting, contribute to cancer cachexia.
  • Understanding liver mechanisms is crucial for cachexia pathogenesis.

Purpose of the Study:

  • To investigate novel mechanisms of hepatic alterations in cancer cachexia.
  • To explore the role of bile acid metabolism and inflammation in liver dysfunction during cachexia.
  • To evaluate potential therapeutic interventions targeting hepatic pathways.

Main Methods:

  • Transcriptomic analysis of liver tissue in a colon carcinoma 26 cachectic mouse model.
  • Bile acid profiling, mRNA analysis, histology, and western blotting.
  • Interventional studies using anti-interleukin-6 antibody and cholestyramine, validated in colorectal cancer patients.

Main Results:

  • Cachectic mice exhibited altered bile acid, fatty acid, and xenobiotic metabolism pathways.
  • Impaired hepatobiliary transport led to increased hepatic and systemic bile acid levels and liver inflammation.
  • Interleukin-6 reduction and bile acid targeting (cholestyramine) ameliorated hepatic inflammation.
  • Elevated serum bile acids and correlation with systemic inflammation were observed in cachectic patients.

Conclusions:

  • Cancer cachexia is associated with significant alterations in liver bile acid metabolism and hepatobiliary secretion.
  • Systemic inflammation contributes to impaired hepatobiliary transport and hepatic inflammation via bile acids.
  • This study highlights the liver's critical role in cancer cachexia and suggests therapeutic targets.